Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...
Zacks.com on MSN11h
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADCGilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...
The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...
Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...
Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...
Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback